115 related articles for article (PubMed ID: 36167599)
1. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
Devos G; Tosco L; Baldewijns M; Gevaert T; Goffin K; Petit V; Mai C; Laenen A; Raskin Y; Van Haute C; Goeman L; De Meerleer G; Berghen C; Devlies W; Claessens F; Van Poppel H; Everaerts W; Joniau S
Eur Urol; 2023 Jun; 83(6):508-518. PubMed ID: 36167599
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
Tosco L; Laenen A; Gevaert T; Salmon I; Decaestecker C; Davicioni E; Buerki C; Claessens F; Swinnen J; Goffin K; Oyen R; Everaerts W; Moris L; De Meerleer G; Haustermans K; Joniau S;
BMC Cancer; 2018 Apr; 18(1):354. PubMed ID: 29606109
[TBL] [Abstract][Full Text] [Related]
3. The Association Between [
Chen M; Fu Y; Peng S; Zang S; Ai S; Zhuang J; Wang F; Qiu X; Guo H
J Nucl Med; 2023 Oct; 64(10):1550-1555. PubMed ID: 37474268
[TBL] [Abstract][Full Text] [Related]
4. Presurgical
Djaïleb L; Armstrong WR; Thompson D; Gafita A; Farolfi A; Rajagopal A; Grogan TR; Nguyen K; Benz MR; Hotta M; Barbato F; Ceci F; Schwarzenböck SM; Unterrainer M; Zacho HD; Juarez R; Cooperberg M; Carroll P; Washington S; Reiter RE; Eiber M; Herrmann K; Fendler WP; Czernin J; Hope TA; Calais J
Eur Urol; 2023 Dec; 84(6):588-596. PubMed ID: 37482512
[TBL] [Abstract][Full Text] [Related]
5. Baseline PSMA-PET/CT as a predictor of PSA persistence following radical prostatectomy in high-risk nonmetastatic prostate cancer patients receiving neoadjuvant therapy.
Du X; Dong Y; Liu J; Su Y; Zhu Y; Pan J; Dong B; Chen R; Liu J; Tong Z; Pienta KJ; Rowe SP; Dong L; Xue W
Prostate; 2023 Aug; 83(11):1112-1120. PubMed ID: 37165552
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial.
Fleshner NE; Sayyid RK; Hansen AR; Chin JLK; Fernandes R; Winquist E; van der Kwast T; Sweet J; Lajkosz K; Kenk M; Hersey K; Veloso R; Berlin D; Herrera-Caceres JO; Sridhar S; Moussa M; Finelli A; Hamilton RJ; Kulkarni GS; Zlotta AR; Joshua AM
Clin Cancer Res; 2023 Oct; 29(19):3867-3874. PubMed ID: 37439809
[TBL] [Abstract][Full Text] [Related]
7. The role of PSMA PET/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer.
Esen B; Seymen H; Gurses B; Armutlu A; Koseoglu E; Tarim K; Ertoy Baydar D; Sarikaya AF; Canda AE; Balbay D; Kordan Y; Tilki D; Esen T; Demirkol MO
Prostate; 2024 Jan; 84(1):32-38. PubMed ID: 37661579
[TBL] [Abstract][Full Text] [Related]
8. Administering [
Eapen RS; Buteau JP; Jackson P; Mitchell C; Oon SF; Alghazo O; McIntosh L; Dhiantravan N; Scalzo MJ; O'Brien J; Sandhu S; Azad AA; Williams SG; Sharma G; Haskali MB; Bressel M; Chen K; Jenjitranant P; McVey A; Moon D; Lawrentschuk N; Neeson PJ; Murphy DG; Hofman MS
Eur Urol; 2024 Mar; 85(3):217-226. PubMed ID: 37891072
[TBL] [Abstract][Full Text] [Related]
9. Benign Prostatic Hyperplasia-Related False-Positive of Prostate-Specific Membrane Antigen-Positron Emission Tomography in the Diagnosis of Prostate Cancer: The Achilles' Heel of Biopsy-Free Radical Prostatectomy?
Tang W; Tang Y; Qi L; Zhang Y; Tang G; Gao X; Hu S; Cai Y
J Urol; 2023 Dec; 210(6):845-855. PubMed ID: 37647549
[TBL] [Abstract][Full Text] [Related]
10. Correlation between pre-radical prostatectomy standardized SUVmax ratios detected on 68Ga-PSMA-I&T PET/CT and final histopathology outcomes: an in-depth analysis.
Arıkan MG; Soyluoğlu S; Korkmaz Ü; Taştekin E; Elboğa U; Arda E
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024; 43(2):100-106. PubMed ID: 38331250
[TBL] [Abstract][Full Text] [Related]
11. Changes in bone and mineral homeostasis after short-term androgen deprivation therapy with or without androgen receptor signalling inhibitor - substudy of a single-centre, double blind, randomised, placebo-controlled phase 2 trial.
David K; Devos G; Narinx N; Antonio L; Devlies W; Deboel L; Schollaert D; Eisenhauer A; Cavalier E; Vanderschueren D; Claessens F; Joniau S; Decallonne B
EBioMedicine; 2023 Nov; 97():104817. PubMed ID: 37804569
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer.
Wei Y; Zhang R; Zhong D; Chen Z; Chen G; Yang M; Lin L; Li T; Ye L; Chen L; Zhu Q
Front Pharmacol; 2023; 14():1284899. PubMed ID: 37927597
[TBL] [Abstract][Full Text] [Related]
13. Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial.
McKay RR; Xie W; Yang X; Acosta A; Rathkopf D; Laudone VP; Bubley GJ; Einstein DJ; Chang P; Wagner AA; Kane CJ; Preston MA; Kilbridge K; Chang SL; Choudhury AD; Pomerantz MM; Trinh QD; Kibel AS; Taplin ME
Cancer; 2024 May; 130(9):1629-1641. PubMed ID: 38161319
[TBL] [Abstract][Full Text] [Related]
14. Lymphotropic Pattern of Prostate-specific Membrane Antigen-detected Metastases Among Biochemically Recurrent Radical Prostatectomy Patients with Cribriform Disease.
Bernardino R; Sayyid RK; Al-Daqqaq Z; Tiwari R; Cockburn J; Vijayakanthan S; Qaoud Y; Berjaoui MB; Metser U; Berlin A; van der Kwast T; Fleshner NE
Eur Urol Focus; 2023 Nov; 9(6):1016-1023. PubMed ID: 37268513
[TBL] [Abstract][Full Text] [Related]
15. Protocol for SNOTOB study: radical prostatectomy without prostate biopsy following
Wang C; Dong Q; Liu X; Ni M; Xie Q; Xiao J; Tao T
BMJ Open; 2023 Nov; 13(11):e073983. PubMed ID: 37984956
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of
Zheng A; Wang Z; Luo L; Chang R; Gao J; Wang B; Duan X
Front Oncol; 2023; 13():1169189. PubMed ID: 37234988
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Degarelix in the Neoadjuvant Setting in Managing Locally Advanced Prostate Cancer.
Sankaran S; Govindaswamy TG; Dholakia K; Selvaraj N; Kanan D; Tiwari M; Ragavan N
Cureus; 2023 Jun; 15(6):e40752. PubMed ID: 37363117
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study.
Rajwa P; Robesti D; Chaloupka M; Zattoni F; Giesen A; Huebner NA; Krzywon A; Miszczyk M; Moll M; Stando R; Cisero E; Semko S; Checcucci E; Devos G; Apfelbeck M; Gatti C; Marra G; van den Bergh RCN; Goldner G; Rasul S; Ceci F; Dal Moro F; Porpiglia F; Gontero P; Bjartell A; Stief C; Heidenreich A; Joniau S; Briganti A; Shariat SF; Gandaglia G;
Eur Urol Oncol; 2023 Oct; ():. PubMed ID: 37845121
[TBL] [Abstract][Full Text] [Related]
19. Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy.
Dirix P; Strijbos M; den Mooter TV; Liefhooghe N; Bruwaene SV; Uvin P; Ghysel C; Ost D; Schatteman P; Bral S; Engels B; den Begin RV; Otte FX; Roumeguere T; Palumbo S; Neybuch Y; Fonteyne V; Ost P; Dirix L
Future Oncol; 2020 Jun; 16(16):1083-1189. PubMed ID: 32356465
[TBL] [Abstract][Full Text] [Related]
20. Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol.
Calleris G; Filleron T; Kesch C; Roubaud G; Pradère B; Cabarrou B; Malavaud B; Roupret M; Mourey L; Ploussard G
Eur Urol Oncol; 2023 Oct; ():. PubMed ID: 37806843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
